ChAdOx1-S[recombinant] (COVID-19 Vaccine AstraZeneca)

• On 28 January 2021, the Food and Drug Administration (FDA) issued authorization granting AstraZeneca Pharmaceuticals (Phils.) Inc. the emergency use approval of COVID-19 vaccine ChAdOx1-S[recombinant] (COVID-19 Vaccine AstraZeneca)

               Product Information
               English    Tagalog
               Patient Information Leaflet
               English    Tagalog

• The  COVID-19 Vaccine AstraZeneca is authorized on the basis of regulatory reliance to the Medicine and Healthcare products Regulatory Agency (MHRA) of the United Kingdom.
• Information regarding COVID-19 Vaccine AstraZeneca is being updated regularly and is available here.
• Information on the safety of AstraZeneca COVID-19 Vaccine is discussed in their comprehensive Risk Management Plan.
• For more information on reporting side effects, click here.